Tanespimycin in Treating Patients With Stage III-IV Melanoma

NCT ID: NCT00087386

Last Updated: 2013-04-10

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2004-06-30

Brief Summary

This phase II trial is studying how well tanespimycin works in treating patients with stage III or stage IV melanoma. Antitumor antibiotics such as tanespimycin may stop the growth of melanoma by stopping blood flow to the tumor.

Detailed Description

PRIMARY OBJECTIVES:

I. Determine if treatment with 17-AAG results in measurable anti-tumor effects and calculate the proportion of clinical responses.

II. Test the hypothesis that treatment with 17-AAG can disrupt the MAPK pathway by depleting intra-tumor stores of RAF kinases and/or downstream proteins such as phospho-ERK, CDK4 and cyclin D1.

III. Determine if either of these effects correlates with the presence of mutated BRAF within the melanoma tumor.

OUTLINE: This is a multicenter study. Patients are stratified according to presence of BRAF mutation in tumor (yes vs no).

Patients receive tanespimycin IV over 1-6 hours once weekly for 6 weeks. Courses repeat every 56 days in the absence of disease progression or unacceptable toxicity.

Conditions

Recurrent Melanoma; Stage III Melanoma; Stage IV Melanoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treatment (tanespimycin)

Patients receive tanespimycin IV over 1-6 hours once weekly for 6 weeks. Courses repeat every 56 days in the absence of disease progression or unacceptable toxicity.

Group Type: EXPERIMENTAL

tanespimycin

Intervention Type: DRUG

Given IV

laboratory biomarker analysis

Intervention Type: OTHER

Correlative studies

Interventions

tanespimycin

Given IV

Intervention Type: DRUG

laboratory biomarker analysis

Correlative studies

Intervention Type: OTHER

Other Intervention Names

17-AAG

Eligibility Criteria

Inclusion Criteria

• Histologically or cytologically confirmed melanoma

• Stage III or IV disease
• No primary melanoma of the choroid or mucosa
• Measurable disease

• At least 1 unidimensionally measurable lesion >= 20 mm by conventional techniques OR >= 10 mm by spiral CT scan
• Tumor amenable to biopsy (for the first 10 patients in each stratum only)

• Patients must have measurable disease in addition to the tumor(s) to be biopsied
• No brain or epidural metastases

• Completely resected solitary brain metastases allowed provided patient has been free of CNS metastases for >= 6 months
• Performance status - Karnofsky 60-100%
• Performance status - ECOG 0-2
• More than 3 months
• Absolute neutrophil count >= 1,500/mm^3
• Platelet count >= 100,000/mm^3
• WBC >= 3,000/mm^3
• AST and ALT =< 2.5 times upper limit of normal
• Creatinine normal
• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia
• No history of myocardial infarction
• No history of prolonged QTc interval
• No active ischemic heart disease within the past 12 months
• No uncontrolled dysrhythmia or dysrhythmias requiring medication
• No congenital prolonged QT syndrome
• No left bundle branch block
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No prior allergic reaction attributed to compounds of similar chemical or biological composition to 17-N-allylamino-17-demethoxygeldanamycin (17-AAG)
• No prior serious allergic reaction to eggs
• No other uncontrolled illness
• No active or ongoing infection requiring systemic antimicrobial treatment
• No psychiatric illness or social situation that would preclude study compliance
• No more than 1 prior chemotherapy regimen for metastatic melanoma

• Prior vaccines, cytokines, or interferon alfa is not considered prior therapy unless administered with a chemotherapy drug
• More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
• Prior radiotherapy dose =< 3,000 cGy to fields including substantial marrow
• More than 4 weeks since prior radiotherapy and recovered
• No prior radiotherapy field that included the heart (e.g., mantle)
• No concurrent combination antiretroviral therapy for HIV-positive patients
• No concurrent medications that may prolong the QTc interval
• No other concurrent anticancer therapy
• No other concurrent investigational agents
• No concurrent treatment with any of the following medications or herbal remedies:

• Inhibitors of CYP3A4:

• Fluconazole
• Itraconazole
• Ketoconazole
• Macrolide antibiotics (azithromycin, clarithromycin, erythromycin, or troleandomycin)
• Midazolam
• Nifedipine
• Verapamil
• Diltiazem
• Terfenadine
• Cyclosporine
• Cisapride
• Inducers of CYP3A4:

• Carbamazepine
• Phenobarbital
• Phenytoin
• Rifampin
• Herbal extracts and tinctures with CYP3A4 inhibitory activity:

• Hydrastis canadensis (goldenseal)
• Hypericum perforatum (St. John's wort)
• Uncaria tomentosa (cat's claw)
• Echinacea angustifolia roots
• Trifolium pratense (wild cherry)
• Matricaria chamomilla (chamomile)
• Glycyrrhiza glabra (licorice)
• Dillapiol
• Hypericin
• Naringin
• No other concurrent herbal extracts

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Paul Chapman

Role: PRINCIPAL_INVESTIGATOR

Memorial Sloan Kettering Cancer Center

Locations

Memorial Sloan-Kettering Cancer Center

New York, New York, United States

Countries

United States

Other Identifiers

04-056

Identifier Type: -

Identifier Source: secondary_id

NCI-6480

Identifier Type: -

Identifier Source: secondary_id

CDR0000374980

Identifier Type: -

Identifier Source: secondary_id

MSKCC-04056

Identifier Type: -

Identifier Source: secondary_id

N01CM62206

Identifier Type: NIH

Identifier Source: secondary_id

View Link

NCI-2012-01453

Identifier Type: -

Identifier Source: org_study_id